Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRB | P28702 | 4/20 | 0.46 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21906513 | 0.89 | RXRB (0.46) | RXRBHSPB1PTGS1PTGS2 | |
| SCHEMBL21906363 | 0.89 | RXRB (0.46) | RXRBHSPB1MAPK14PTGS1PTGS2 | |
| SCHEMBL21907354 | 0.88 | RXRB (0.47) | RXRBPTGS1PTGS2 | |
| SCHEMBL21907350 | 0.88 | MEN1 (0.45) | RXRBMAPK8 | |
| SCHEMBL21906497 | 0.82 | L3MBTL1 (0.46) | RXRBHSPB1 | |
| SCHEMBL21906532 | 0.80 | RXRB (0.45) | RXRBHSPB1TRPA1 | |
| SCHEMBL21906519 | 0.79 | RXRB (0.45) | RXRB | |
| SCHEMBL21906704 | 0.79 | RXRB (0.43) | RXRB | |
| SCHEMBL21906355 | 0.78 | HSPB1 (0.49) | RXRBHSPB1TRPA1MAPK14 | |
| SCHEMBL21906697 | 0.78 | HTT (0.45) | RXRBPTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3867244-B1 | 4-PYRAZIN-2-YLMETHYL-MORPHOLINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INT (DE) | 2023-01-18 | — | — | EP | disclosed |
| US-20210393644-A1 | 4-Pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament | BOEHRINGER INGELHEIM INT (DE) | 2021-12-23 | — | — | US | disclosed |
| US-11166958-B2 | 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-11-09 | — | — | US | disclosed |
| US-20200121691-A1 | 4-Pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2020-04-23 | — | — | US | disclosed |
| WO-2020079039-A1 | 4-PYRAZIN-2-YLMETHYL-MORPHOLINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200121691-A1 | 4-Pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament | GRIN2A, GRIN2C, GRIN3A | RXRB 595/4885HSPB1 3171/4885TRPA1 306/4885 |
| US-20210393644-A1 | 4-Pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament | GRIN2A, GRIN2C, GRIN3A | RXRB 595/4885HSPB1 3171/4885TRPA1 306/4885 |
| US-11166958-B2 | 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament | GRIN2A, GRIN2C, GRIN3A | RXRB 595/4885HSPB1 3171/4885TRPA1 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.